The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.

Abstract:

:Intranasal (i.n.) immunization of BALB/c mice with chimeric murine rotavirus EDIM (epizootic diarrhea of infant mice) VP6 and attenuated E. coli heat-labile toxin (LT), LT(R192G), stimulated >99% protection against rotavirus shedding after EDIM challenge. Here, we evaluated other potential adjuvants with chimeric VP6 administered by two mucosal routes: i.n. and oral. Besides LT(R192G), the adjuvants examined included Adjumer, CpG oligodeoxynucleotides (CpG ODN), chimeric A1 subunit of cholera toxin (CTA1)-DD, and QS-21. All except QS-21 significantly (P<0.05) increased VP6-specific serum IgG responses after i.n. immunization, but none significantly increased these responses when administered orally. The i.n. delivery of chimeric VP6 alone induced both rotavirus IgG1 and IgG2a whose relative titers suggested a skewed Th2-like response. Inclusion of Adjumer greatly increased Th2-like responses, while CpG ODN shifted the response to a less Th2-like response. The adjuvants CTA1-DD, LT(R192G), QS-21 had no significant effect on ratios of IgG1/IgG2a titers. Following EDIM challenge of mice immunized i.n. with chimeric VP6 and either LT(R192G), CTA1-DD, Adjumer or CpG ODN, shedding was reduced >99, 95, 80, 74, respectively, relative to that found in unimmunized mice (P<0.05). QS-21 induced less protection (43%, not significant (N.S.)) while immunization with chimeric VP6 alone reduced shedding by only 16% (N.S.). Oral immunization with chimeric VP6 and all selected adjuvants except QS-21 was less effective than after i.n. immunization, with protection levels of 94 (P<0.05), 71 (P<0.05), 55, 35 and 28% for LT(R192G), QS-21, CpG ODN, CTA1-DD, and Adjumer, respectively, while immunization with chimeric VP6 alone gave no protection. Thus, different adjuvants induced different degrees of protection and oral immunization was generally less effective then the i.n. route.

journal_name

Vaccine

journal_title

Vaccine

authors

Choi AH,McNeal MM,Flint JA,Basu M,Lycke NY,Clements JD,Bean JA,Davis HL,McCluskie MJ,VanCott JL,Ward RL

doi

10.1016/s0264-410x(02)00043-9

subject

Has Abstract

pub_date

2002-03-15 00:00:00

pages

1733-40

issue

13-14

eissn

0264-410X

issn

1873-2518

pii

S0264410X02000439

journal_volume

20

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Enhancement of antibody response of turkeys to trivalent avian influenza vaccine by positively charged liposomal avridine adjuvant.

    abstract::Trivalent avian influenza (AIV) antigens (H4N8, H5N2 and H7N3), mixed with positively charged, negatively charged and neutral avridine-containing liposomes, and oil-emulsion were subcutaneously administered to 6-week-old turkeys. Charged liposomal avridine adjuvant, either positive or negative, produced a better antib...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(92)90444-o

    authors: Fatunmbi OO,Newman JA,Sivanandan V,Halvorson DA

    更新日期:1992-01-01 00:00:00

  • Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis.

    abstract::Malaria represents a major global health problem but despite extensive efforts, no effective vaccine is available. Various vaccine candidates have been developed that provide protection in animal models, such as a gene gun-delivered DNA vaccine encoding the circumsporozoite protein (CSP) of Plasmodium berghei. A commo...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.06.059

    authors: Bergmann-Leitner ES,Leitner WW,Duncan EH,Savranskaya T,Angov E

    更新日期:2009-09-18 00:00:00

  • An assessment of risk compensation and spillover behavioural adaptions associated with the use of vaccines in animal disease management.

    abstract::This paper analyses farmers' behavioural responses to Government attempts to reduce the risk of disease transmission from badgers to cattle through badger vaccination. Evidence for two opposing behavioural adaptions is examined in response to the vaccination of badgers to reduce the risk of transmission to farmed catt...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.11.037

    authors: Enticott G,Maye D,Naylor R,Brunton L,Downs SH,Donnelly CA

    更新日期:2020-01-29 00:00:00

  • Immunogenicity and protective efficacy of a novel foot-and-mouth disease virus empty-capsid-like particle with improved acid stability.

    abstract::Foot-and-mouth disease virus (FMDV) is the etiological agent of a highly contagious disease that affects cloven-hoofed animal species. The FMDV capsid is highly acid labile and viral particles lose their immunogenicity when they disassemble at mildly acidic pHs. The viral capsid of FMDV serotype O is more sensitive th...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.02.032

    authors: Xie Y,Li H,Qi X,Ma Y,Yang B,Zhang S,Chang H,Yin X,Li Z

    更新日期:2019-03-28 00:00:00

  • Oral delivery of wafers made from HBsAg-expressing maize germ induces long-term immunological systemic and mucosal responses.

    abstract:BACKGROUND:The hepatitis B surface antigen (HBsAg) has been administered over the last 20 years as a parenteral vaccine against the hepatitis B virus (HBV). Despite high seroconversion rates, chronic infection rates are still high worldwide. Orally delivered vaccines provide a practical alternative to injected vaccines...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.04.080

    authors: Hayden CA,Fischer ME,Andrews BL,Chilton HC,Turner DD,Walker JH,Tizard IR,Howard JA

    更新日期:2015-06-09 00:00:00

  • A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.

    abstract::Pneumococcal and Salmonella typhi infections are two major diseases for children in developing countries. For typhoid fever, licensed Vi polysaccharide vaccines are ineffective in children <2-year old. While investigational Vi conjugate vaccines have been shown effective in clinical trials, they are currently only ava...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.03.039

    authors: Lu YJ,Zhang F,Sayeed S,Thompson CM,Szu S,Anderson PW,Malley R

    更新日期:2012-05-14 00:00:00

  • What is the responsibility of national government with respect to vaccination?

    abstract::Given the ethical aspects of vaccination policies and current threats to public trust in vaccination, it is important that governments follow clear criteria for including new vaccines in a national programme. The Health Council of the Netherlands developed such a framework of criteria in 2007, and has been using this ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.10.008

    authors: Verweij MF,Houweling H

    更新日期:2014-12-12 00:00:00

  • Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.

    abstract::In a randomized, placebo-controlled, monocenter, observer blinded study conducted in an area where dengue is endemic, we assessed the safety and immunogenicity of a recombinant, live, attenuated, tetravalent dengue vaccine candidate (CYD-TDV) in 2-11 year-olds with varying levels of pre-existing yellow-fever immunity ...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2012.07.043

    authors: Lanata CF,Andrade T,Gil AI,Terrones C,Valladolid O,Zambrano B,Saville M,Crevat D

    更新日期:2012-09-07 00:00:00

  • Intranasal vaccination with ebola virus GP amino acids 258-601 protects mice against lethal challenge.

    abstract::Ebola virus (EBOV) disease (EVD) leads to lethal hemorrhagic fever with a case fatality rate as high as 90%, thus posing a serious global public health concern. However, while several vaccines based on the EBOV glycoprotein have been confirmed to be effective in animal experiments, no licensed vaccines or effective tr...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.09.003

    authors: Su QD,He SH,Yi Y,Qiu F,Lu XX,Jia ZY,Meng QL,Fan XT,Tian RG,Audet J,Qiu XG,Bi SL

    更新日期:2018-10-01 00:00:00

  • A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice.

    abstract::Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) is contracted via aerosol infection, typically affecting the lungs. Mycobacterium bovis bacillus Calmette-Guerin (BCG) is the only licensed vaccine and has variable efficacy in protecting against pulmonary TB. Additionally, chemotherapy is associated with l...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.07.073

    authors: Ahmed M,Smith DM,Hamouda T,Rangel-Moreno J,Fattom A,Khader SA

    更新日期:2017-09-05 00:00:00

  • Penton-dodecahedron of fowl adenovirus serotype 4 as a vaccine candidate for the control of related diseases.

    abstract::In some serotypes of adenovirus (Ad), the penton base and attached trimeric fiber assemble into dodecameric virus-like particles called penton-dodecahedron (Pt-Dd), which can be internalized and used to deliver the vaccine antigens and drugs. Fowl adenovirus serotype 4 (FAdV-4) is an important pathogen, causing seriou...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.12.041

    authors: Wang X,Tang Q,Qiu L,Yang Z

    更新日期:2019-02-04 00:00:00

  • Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles.

    abstract::Aluminum salts such as aluminum oxyhydroxide and aluminum hydroxyphosphate are commonly used human vaccine adjuvants. In an effort to improve the adjuvant activity of aluminum salts, we previously showed that the adjuvant activity of aluminum oxyhydroxide nanoparticles is significantly more potent than that of aluminu...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.04.081

    authors: Ruwona TB,Xu H,Li X,Taylor AN,Shi YC,Cui Z

    更新日期:2016-06-08 00:00:00

  • Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials.

    abstract:BACKGROUND:Efforts to develop a Clostridium difficile vaccine are underway; identification of patients at risk for C. difficile infection (CDI) is critical to inform vaccine trials. We identified groups at high risk of CDI ≥ 2 8 days after hospital discharge. METHODS:Hospital discharge data and pharmacy data from two ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.09.078

    authors: Baggs J,Yousey-Hindes K,Ashley ED,Meek J,Dumyati G,Cohen J,Wise ME,McDonald LC,Lessa FC

    更新日期:2015-11-17 00:00:00

  • Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.

    abstract::Toxoplasma gondii is an intracellular parasite that causes severe neurologic and ocular disease in immune-compromised and congenitally infected individuals. There is no vaccine protective against human toxoplasmosis. Herein, immunization of L(d) mice with HF10 (HPGSVNEFDF) with palmitic acid moieties or a monophosphor...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.03.028

    authors: Tan TG,Mui E,Cong H,Witola WH,Montpetit A,Muench SP,Sidney J,Alexander J,Sette A,Grigg ME,Maewal A,McLeod R

    更新日期:2010-05-21 00:00:00

  • Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies.

    abstract::A HIV-1 tier system has been developed to categorize the various subtype viruses based on their sensitivity to vaccine-induced neutralizing antibodies (NAbs): tier 1 with greatest sensitivity, tier 2 being moderately sensitive, and tier 3 being the least sensitive to NAbs (Mascola et al., J Virol 2005; 79:10103-7). He...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.05.024

    authors: Coleman JK,Pu R,Martin MM,Noon-Song EN,Zwijnenberg R,Yamamoto JK

    更新日期:2014-02-03 00:00:00

  • Laboratory and field evaluation of Schistosoma japonicum DNA vaccines in sheep and water buffalo in China.

    abstract::Vaccines are needed to control zoonotic Schistosoma japonicum infection and several vaccine candidates have now been identified. Two of these (Sj28GST and Sj23) have shown particular promise in sheep when injected with Freund's adjuvants. The objective of the present work was to find a vaccine formulation which may ha...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00340-1

    authors: Shi F,Zhang Y,Ye P,Lin J,Cai Y,Shen W,Bickle QD,Taylor MG

    更新日期:2001-11-12 00:00:00

  • BHV-1 DNA vaccination: effect of the adjuvant RN-205 on the modulation of the immune response in mice.

    abstract::It is well documented that adjuvants improve the immune response generated by traditional viral vaccines, but less is known about the effects of adjuvants on the immune response elicited by DNA vaccines. In this study, we have investigated the use of RN-205 (immunomodulator containing a membrane rich in lipopolysaccha...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(02)00211-6

    authors: Zamorano P,Taboga O,Domínguez M,Romera A,Puntel M,Tami C,Mongini C,Waldner C,Palma E,Sadir A

    更新日期:2002-06-21 00:00:00

  • Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing.

    abstract:BACKGROUND:Better understanding of vaccine reactogenicity is crucial given its potential impact upon vaccine safety and acceptance. Here we report a comparison between conventional and novel (continuous) methods of monitoring temperature and evaluate any association between reactogenicity and the monocyte activation te...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.10.023

    authors: Valente Pinto M,Davis K,Andrews N,Goldblatt D,Borrow R,Southern J,Nordgren IK,Vipond C,Plested E,Miller E,Snape MD

    更新日期:2020-11-17 00:00:00

  • A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.

    abstract::West Nile virus (WNV) has caused multiple global outbreaks with increased frequency of neuroinvasive disease in recent years. Despite many years of research, there are no licensed therapeutics or vaccines available for human use. One of the major impediments of vaccine development against WNV is the potential enhancem...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.02.073

    authors: Lai H,Paul AM,Sun H,He J,Yang M,Bai F,Chen Q

    更新日期:2018-03-27 00:00:00

  • Human monkeypox - After 40 years, an unintended consequence of smallpox eradication.

    abstract::Smallpox eradication, coordinated by the WHO and certified 40 years ago, led to the cessation of routine smallpox vaccination in most countries. It is estimated that over 70% of the world's population is no longer protected against smallpox, and through cross-immunity, to closely related orthopox viruses such as monke...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.04.062

    authors: Simpson K,Heymann D,Brown CS,Edmunds WJ,Elsgaard J,Fine P,Hochrein H,Hoff NA,Green A,Ihekweazu C,Jones TC,Lule S,Maclennan J,McCollum A,Mühlemann B,Nightingale E,Ogoina D,Ogunleye A,Petersen B,Powell J,Quantick O

    更新日期:2020-07-14 00:00:00

  • PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.

    abstract::The highly pathogenic avian H5N1 influenza virus has the potential to incite a global pandemic. Therefore, there is an urgent need to develop effective vaccines against these viruses. Because it is difficult to predict which strain of influenza will cause a pandemic, it is advantageous to develop vaccines that will co...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.04.074

    authors: Ichinohe T,Ainai A,Tashiro M,Sata T,Hasegawa H

    更新日期:2009-10-23 00:00:00

  • Production of yellow fever virus in microcarrier-based Vero cell cultures.

    abstract::In this work, the propagation of the 17DD yellow fever virus in Vero cells grown on Cytodex-1 microcarriers was evaluated. After verifying that upon infection the virus adsorption step could be performed under continuous agitation, experiments were carried out in spinners and sparged lab-scale stirred-tank bioreactor ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.06.023

    authors: Souza MC,Freire MS,Schulze EA,Gaspar LP,Castilho LR

    更新日期:2009-10-30 00:00:00

  • Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.

    abstract::ADVAX is a DNA-based candidate HIV vaccine that was safe but weakly immunogenic when delivered intramuscularly (IM) in humans. Studies were performed in animal models to determine whether an alternative delivery method, in vivo electroporation (EP), could improve the immunogenicity of ADVAX while maintaining an accept...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.11.011

    authors: Dolter KE,Evans CF,Ellefsen B,Song J,Boente-Carrera M,Vittorino R,Rosenberg TJ,Hannaman D,Vasan S

    更新日期:2011-01-17 00:00:00

  • Correlates of protection of serotype-specific capsular antibody and invasive Group B Streptococcus disease in South African infants.

    abstract:BACKGROUND:Vaccinating pregnant women may prevent invasive Group B Streptococcus (GBS) disease in their young infants. In a low-middle income setting, we sought to determine an association between natural maternal antibody responses and the development of invasive GBS disease. METHODS:We undertook a matched case-contr...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.10.019

    authors: Dangor Z,Kwatra G,Izu A,Adrian P,Cutland CL,Velaphi S,Ballot D,Reubenson G,Zell ER,Lala SG,Madhi SA

    更新日期:2015-11-27 00:00:00

  • Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older.

    abstract::A multi-centre, randomised, double-blinded, active-controlled, parallel-group clinical trial was carried out to assess the immunogenicity and safety of NBP608-a newly developed live-attenuated zoster vaccine in Korea-relative to Zostavax® in healthy adults aged 50 years or older. Immune responses to the vaccine were e...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2019.04.046

    authors: Choi WS,Choi JH,Jung DS,Choi HJ,Kim YS,Lee J,Jang HC,Shin EC,Park JS,Kim H,Cheong HJ

    更新日期:2019-06-12 00:00:00

  • Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella.

    abstract:BACKGROUND:Germany introduced routine varicella (V) vaccination in 2004. Due to a slightly increased risk of febrile convulsions after first-dose application of combined measles-mumps-rubella-varicella (MMRV) vaccine separate first-dose vaccinations with MMR and monovalent V vaccine were recommended in September 2011. ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.12.065

    authors: Streng A,Liese JG

    更新日期:2014-02-12 00:00:00

  • The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice.

    abstract::Recently the urgency of developing a pandemic influenza vaccine has lead to the re-evaluation of the use of whole virus vaccine. We have compared the humoral immune response and the protective efficacy of whole and split influenza virus vaccines in mice. Whole virus vaccine was more immunogenic particularly after the ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.05.040

    authors: Cox RJ,Hovden AO,Brokstad KA,Szyszko E,Madhun AS,Haaheim LR

    更新日期:2006-11-10 00:00:00

  • Regulatory considerations on new adjuvants and delivery systems.

    abstract::New and improved vaccines and delivery systems are increasingly being developed for prevention, treatment and diagnosis of human diseases. Prior to their use in humans, all new biological products must undergo pre-clinical evaluation. These pre-clinical studies are important not only to establish the biological proper...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2005.01.135

    authors: Sesardic D

    更新日期:2006-04-12 00:00:00

  • Process development for the mass production of Ehrlichia ruminantium.

    abstract::This work describes the optimization of a cost-effective process for the production of an inactivated bacterial vaccine against heartwater and the first attempt to produce the causative agent of this disease, the rickettsia Ehrlichia ruminantium (ER), using stirred tanks. In vitro, it is possible to produce ER using c...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.08.109

    authors: Marcelino I,Sousa MF,Veríssimo C,Cunha AE,Carrondo MJ,Alves PM

    更新日期:2006-03-06 00:00:00

  • The web and public confidence in MMR vaccination in Italy.

    abstract::Measles, mumps and rubella (MMR) vaccination coverage in Italy has been decreasing starting from 2012 and, at the present, none of the Italian regions has achieved the goal of 95% coverage target. A decision of the Court of Justice of Rimini in March 2012 that awarded vaccine-injury compensation for a case of autism h...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.07.029

    authors: Aquino F,Donzelli G,De Franco E,Privitera G,Lopalco PL,Carducci A

    更新日期:2017-08-16 00:00:00